Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC Programme
- 28 February 2001
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 39 (2), 125-127
- https://doi.org/10.1016/s0732-8893(00)00222-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens StrainsAntimicrobial Agents and Chemotherapy, 2000
- The MYSTIC (meropenem yearly susceptibility test information collection) programmeInternational Journal of Antimicrobial Agents, 1999
- Important and Emerging β-Lactamase-mediated Resistances in Hospital-based Pathogens: The Amp C EnzymesDiagnostic Microbiology and Infectious Disease, 1998
- Contribution of overproduced chromosomal beta-lactamase and defective outer membrane porins to resistance to extended-spectrum beta-lactam antibiotics in Serratia marcescensJournal of Antimicrobial Chemotherapy, 1998
- Serratia marcescensJournal of Medical Microbiology, 1997
- Molecular characterization of the Serratia marcescens OmpF porin, and analysis of S. marcescens OmpF and OmpC osmoregulationMicrobiology, 1997
- A functional classification scheme for beta-lactamases and its correlation with molecular structureAntimicrobial Agents and Chemotherapy, 1995
- Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescensAntimicrobial Agents and Chemotherapy, 1995
- Characterization of a New Plasmid-mediated Extended-spectrum .BETA.-Lactamase from Serratia marcescens.The Journal of Antibiotics, 1995
- Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6Antimicrobial Agents and Chemotherapy, 1994